Jyong Biotech Ltd. Ordinary Shares

NASDAQ:MENS

Biotechnology

Healthcare
$1.86 -1.41%

-$0.02 today

Market cap
$141.41M
Beta
2.08
P/E (TTM)
-25.1
EPS (TTM)
-$0.06
52W Low $1.43High $67.00

Volume 0.07M

Average 0.10M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$3.04M

FY 2025 · Annual

Investing Cash Flow

-$13.51M

FY 2025 · Annual

Financing Cash Flow

$17.63M

FY 2025 · Annual

+786.1% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(4.2M)(6.63M)(4.4M)(3.02M)(4.67M)
Depreciation & Amortization122K123K127K120K100K
Deferred Income Tax00000
Stock-Based Compensation00000
Change in Working Capital1.24M2.94M1.12M(1.49M)20.74M
Accounts Receivables00000
Inventory00000
Accounts Payables21K(28K)(2K)1K(1K)
Other Working Capital1.22M2.97M1.12M(1.49M)20.74M
Other Non-Cash Items849K599K554K761K(19.21M)
Operating Cash Flow(1.98M)(2.97M)(2.6M)(3.62M)(3.04M)
Capital Expenditures(137K)(246K)000
Acquisitions (Net)00000
Purchases of Investments(1.83M)(292K)00(16.87M)
Sales of Investments664K1.93M95K016.87M
Other Investing Activities0000(13.51M)
Investing Cash Flow(1.31M)1.39M95K0(13.51M)
Debt Repayment(1.35M)3.61M2.47M2.2M(24K)
Common Stock Issued000017.77M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(35K)(276K)(445K)(213K)(114K)
Financing Cash Flow(1.38M)3.33M2.03M1.99M17.63M
Effect of Forex Changes67K(31K)(54K)(7K)(8K)
Net Change in Cash(4.61M)1.72M(532K)(1.64M)1.08M
Free Cash Flow(2.12M)(3.22M)(2.6M)(3.62M)(3.04M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$4.7M
+ D&A$100.0K
+ Stock-Based Comp$0
+ Deferred Tax$0
+ Working Capital$20.7M
- Other Non-Cash-$19.2M
= Operating Cash Flow-$3.0M
- Capex$0
= Free Cash Flow-$3.0M

Analysis

FY2025 free cash flow is -$3.0M. FCF conversion is 65.1% of net income. Operating cash flow was -$3.0M, with capex of $0. The largest bridge item is Working Capital at $20.7M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
20-F20-F filingMay 15, 2026
NT 20-FNT 20-F filingApr 29, 2026
SC 13DSC 13D filingApr 24, 2026
3Initial statement of beneficial ownershipApr 14, 2026
3Initial statement of beneficial ownershipApr 8, 2026

Does MENS generate free cash flow?

Jyong Biotech Ltd. Ordinary Shares (MENS) generated -$3.04M of free cash flow in fiscal 2025.

How much operating cash flow does MENS produce?

Operating cash flow was -$3.04M, before capital expenditures of $0.00.